Tags

Type your tag names separated by a space and hit enter

Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial.
Br J Psychiatry. 2011 May; 198(5):351-6.BJ

Abstract

BACKGROUND

Two recent clinical studies support the feasibility of trials to evaluate the disease-modifying properties of lithium in Alzheimer's disease, although no benefits were obtained from short-term treatment.

AIMS

To evaluate the effect of long-term lithium treatment on cognitive and biological outcomes in people with amnestic mild cognitive impairment (aMCI).

METHOD

Forty-five participants with aMCI were randomised to receive lithium (0.25-0.5 mmol/l) (n = 24) or placebo (n = 21) in a 12-month, double-blind trial. Primary outcome measures were the modification of cognitive and functional test scores, and concentrations of cerebrospinal fluid (CSF) biomarkers (amyloid-beta peptide (Aβ(42)), total tau (T-tau), phosphorylated-tau) (P-tau).

TRIAL REGISTRATION

NCT01055392.

RESULTS

Lithium treatment was associated with a significant decrease in CSF concentrations of P-tau (P = 0.03) and better perform-ance on the cognitive subscale of the Alzheimer's Disease Assessment Scale and in attention tasks. Overall tolerability of lithium was good and the adherence rate was 91%.

CONCLUSIONS

The present data support the notion that lithium has disease-modifying properties with potential clinical implications in the prevention of Alzheimer's disease.

Links

Publisher Full Text
Aggregator Full Text
Aggregator Full Text

Authors+Show Affiliations

Forlenza OV
Laboratory of Neuroscience (LIM 27) Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, Rua Dr. Ovídio Pires de Campos 785, 05403-010 - São Paulo, SP, Brazil. forlenza@usp.br.
Diniz BS
No affiliation info available
Radanovic M
No affiliation info available
Santos FS
No affiliation info available
Talib LL
No affiliation info available
Gattaz WF
No affiliation info available

MeSH

AgedAlzheimer DiseaseAmyloid beta-PeptidesCognition DisordersDisease ProgressionDouble-Blind MethodGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaHumansLithium CompoundsMiddle AgedNeuropsychological TestsSpinal PunctureTreatment Outcometau Proteins

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

21525519

Clinical Trial Links

Clinical trial which this article describes
Treatment of Psychosis and Agitation in Alzheimer's Disease

Citation

Forlenza, Orestes V., et al. "Disease-modifying Properties of Long-term Lithium Treatment for Amnestic Mild Cognitive Impairment: Randomised Controlled Trial." The British Journal of Psychiatry : the Journal of Mental Science, vol. 198, no. 5, 2011, pp. 351-6.
Forlenza OV, Diniz BS, Radanovic M, et al. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry. 2011;198(5):351-6.
Forlenza, O. V., Diniz, B. S., Radanovic, M., Santos, F. S., Talib, L. L., & Gattaz, W. F. (2011). Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. The British Journal of Psychiatry : the Journal of Mental Science, 198(5), 351-6. https://doi.org/10.1192/bjp.bp.110.080044
Forlenza OV, et al. Disease-modifying Properties of Long-term Lithium Treatment for Amnestic Mild Cognitive Impairment: Randomised Controlled Trial. Br J Psychiatry. 2011;198(5):351-6. PubMed PMID: 21525519.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. AU - Forlenza,Orestes V, AU - Diniz,Breno S, AU - Radanovic,Márcia, AU - Santos,Franklin S, AU - Talib,Leda L, AU - Gattaz,Wagner F, PY - 2011/4/29/entrez PY - 2011/4/29/pubmed PY - 2011/7/22/medline SP - 351 EP - 6 JF - The British journal of psychiatry : the journal of mental science JO - Br J Psychiatry VL - 198 IS - 5 N2 - BACKGROUND: Two recent clinical studies support the feasibility of trials to evaluate the disease-modifying properties of lithium in Alzheimer's disease, although no benefits were obtained from short-term treatment. AIMS: To evaluate the effect of long-term lithium treatment on cognitive and biological outcomes in people with amnestic mild cognitive impairment (aMCI). METHOD: Forty-five participants with aMCI were randomised to receive lithium (0.25-0.5 mmol/l) (n = 24) or placebo (n = 21) in a 12-month, double-blind trial. Primary outcome measures were the modification of cognitive and functional test scores, and concentrations of cerebrospinal fluid (CSF) biomarkers (amyloid-beta peptide (Aβ(42)), total tau (T-tau), phosphorylated-tau) (P-tau). TRIAL REGISTRATION: NCT01055392. RESULTS: Lithium treatment was associated with a significant decrease in CSF concentrations of P-tau (P = 0.03) and better perform-ance on the cognitive subscale of the Alzheimer's Disease Assessment Scale and in attention tasks. Overall tolerability of lithium was good and the adherence rate was 91%. CONCLUSIONS: The present data support the notion that lithium has disease-modifying properties with potential clinical implications in the prevention of Alzheimer's disease. SN - 1472-1465 UR - https://www.unboundmedicine.com/medline/citation/21525519/Disease_modifying_properties_of_long_term_lithium_treatment_for_amnestic_mild_cognitive_impairment:_randomised_controlled_trial_ L2 - https://www.cambridge.org/core/product/identifier/S0007125000255074/type/journal_article DB - PRIME DP - Unbound Medicine ER -